ARX · Accelerant Holdings
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $22.85
Note written ·
Price against the kill line
13.1% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $22.85, on record since 11 November 2026. The shares are up 1.6% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $22.85, well over the $20.25 cash offer, which would show the market pricing a raised or rival bid and the shares leading the S&P 500. A disclosed competing or raised offer above $20.25 would also prove the call wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Financials
Quarter to 30 September 2026, filed 12 November 2026; valuation at the 13 November 2026 close
- Net income, latest quarter ($M)
- −9.2
- Net income, four quarters ($M)
- 67.6
- Shareholders' equity ($M)
- 732
- Price to earnings (×)
- 63.8
- Price to book value (×)
- 5.9
- Revenue, latest quarter ($M)total revenues, including investment gains and losses
- 279
- Revenue, change on a year (%)
- +4.2
- Market value ($M)
- 4,311
Accelerant Holdings is an insurer: net cash, enterprise value and free cash flow are not shown, because a bank's or insurer's cash and investments back its deposits and policies.
All filed numbers
What Accelerant Holdings reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 279 | +4.2 | −0.6 |
| first filed | 357 | +62.9 | 24.5 |
| first filed | 273 | +53.5 | 0.7 |
| first filed | 248 | +30.3 | −0.9 |
| first filed | 267 | +74.0 | −507.7 |
| first filed | 219 | +68.4 | 10.2 |
| Pre-tax income ($M) | −1.6 |
| Net income ($M) four quarters: 67.6 | −9.2 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +5.4 |
| Operating cash flow ($M) | 293 |
| Capital spending ($M) | Not reported |
| Free cash flow ($M) | Not meaningful |
Not meaningful: a bank's or insurer's operating cash flow moves with its deposits, loans and policy reserves, so it is not cash free for its owners.
| Cash and short-term investments ($M) | 2,019 |
| Debt ($M) long-term debt | 120 |
| Net cash, cash less debt ($M) | Not meaningful |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 1,177 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 732 |
Not meaningful: a bank's or insurer's cash and investments back its deposits and policies.
| Market value ($M) | 4,311 |
| Enterprise value, market value plus net debt ($M) | Not meaningful |
| Enterprise value to sales (×) | Not meaningful |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | 63.8 |
| Price to book value (×) | 5.9 |
| Free-cash-flow yield (%) | Not meaningful |
Not meaningful: a bank's or insurer's cash and investments back its deposits and policies.
Not meaningful: a bank's or insurer's operating cash flow moves with its deposits, loans and policy reserves, so it is not cash free for its owners.
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 1.5% of shares outstanding sold short, 2.6 days of average trading to cover, −29.7% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $11K |
| 12 monthsfrom | $888K | $21.6M |
The thesis
Accelerant Holdings is more likely to lag the S&P 500 over the next three months, because its shares trade on a fixed cash price. Thoma Bravo has agreed to pay $20.25 per share, the shares closed at $19.89 on 12 November 2026, and insurance-regulatory approvals plus the shareholder vote decide whether the deal closes in the first half of 2027.
The third-quarter results on 12 November 2026 did not change that. Revenue was $278.6 million, ahead of the $268.7 million estimate cited in news reports. Adjusted earnings per share were $0.18 against a $0.20 estimate. The company held no earnings call and gave no guidance for the fourth quarter or full year 2026. The shares closed at $19.89 that day, within two cents of the prior session.
A completed deal pays a little more than the current close. A broken deal would return the shares to a standalone valuation, with a gross loss ratio that rose to 56.8% in the third quarter. The shares are up 1.6% over three months to 12 November 2026, almost all of it from the re-pricing after the 13 August 2026 announcement.
Bullish and bearish views on Accelerant Holdings
The bull case on Accelerant Holdings (ARX), in brief: voting support is already documented. The bear case: upside is capped by the cash price.
Bull case
- Voting support is already documented. The 13 August 2026 acquisition announcement says Altamont affiliates holding approximately 82% of voting rights agreed to support the merger. The shareholder vote is a lower hurdle than the regulatory approvals.
- No rival bidder emerged. Accelerant said on 23 September 2026 that the go-shop period expired on 22 September 2026 without an alternative proposal. The $20.25 offer is the only disclosed bid.
- Financing is not a closing condition. The 13 August 2026 announcement says Thoma Bravo supplied an equity commitment and that financing availability is not a condition to closing.
- The business kept growing. Exchange written premium, the premium written through Accelerant's platform, reached $1,329.6 million in the third quarter of 2026, up 27% from a year earlier, per the 12 November 2026 release.
- Closing timetable reaffirmed. The 12 November 2026 release repeats that closing is expected in the first half of 2027, subject to customary conditions.
Bear case
- Upside is capped by the cash price. The $19.89 close on 12 November 2026 sits below the $20.25 consideration, the most a completed deal pays per share. Raymond James cited limited upside in its 23 September 2026 downgrade, reported by The Fly, and TD Cowen set a Hold rating with a $20.25 target on 30 September 2026.
- Insurance approvals remain unresolved. The company's releases say closing is subject to shareholder and required regulatory approvals. A formal denial or an unacceptable condition would end the completion case.
- No merger proxy has been filed. The company's SEC filings since August are the 10-Q and results 8-K of 12 November 2026 and a director Form 4, with no merger proxy statement. The 13 August 2026 soliciting material says the company intends to file one for a special shareholder meeting.
- Standalone results are mixed. The gross loss ratio rose to 56.8% in the third quarter of 2026 from 50.1% a year earlier, and the net loss was $9.2 million, per the 12 November 2026 release. These figures matter for the price mainly if the deal fails.
- A director sold near the deal price. An SEC Form 4 shows director Karen Sue Meriwether sold 542 shares at $19.62 on 21 August 2026.
Price setup
The shares closed at $19.89 on 12 November 2026. The 52-week intraday high is $19.91, set on 10 November 2026, and the last close is 0.1% below it. The 50-day average is $19.79 and the 200-day average is $15.23, both as of 12 November 2026. The 52-week closing low is $9.36 on 23 February 2026, before the offer.
Closes from 5 November to 12 November 2026 ran between $19.87 and $19.91. The price moves with deal-completion odds and the expected closing date rather than with operating results, because the buyer pays cash. The 3-month reference close was $19.58 on 14 August 2026, the first session after the announcement.
The $20.25 cash price is the ceiling for a completed deal on the current terms. A close well above it would require the market to price a raised or rival offer.
Catalysts ahead
- Not yet scheduled: Merger proxy statement filed with the SEC. It would disclose the merger background, the retained-equity terms and the shareholder-vote path; none appears among the company's recent SEC filings.
- ~30 June 2027 (est.): Outer edge of the guided first-half-2027 closing window. A later company timetable would show the closing expectation slipping without terminating the merger.
What would change the view
A daily close above $22.85, well over the $20.25 cash offer, which would show the market pricing a raised or rival bid and the shares leading the S&P 500. A disclosed competing or raised offer above $20.25 would also prove the call wrong.
What it trades with
The shares trade on deal terms, not on the specialty-insurance sector. Moves in the broader market matter only through the perceived chance that regulators or the parties turn against the deal. The closest comparison is other cash-merger targets with controlling-holder support, where the price tracks the offer and the expected closing date.
The evidence, claim by claim (7)
- Third-quarter 2026 total revenues were $278.6 million against $267.4 million in the third quarter of 2025; net loss was $9.2 million and adjusted net income $38.2 million (adjusted earnings per diluted share $0.18). Accelerant third-quarter 2026 results release · as of
- Exchange written premium was $1,329.6 million in the third quarter of 2026, up 27% from a year earlier; the gross loss ratio was 56.8% against 50.1% a year earlier. Accelerant third-quarter 2026 results release · as of
- Accelerant said closing of the Thoma Bravo merger is expected in the first half of 2027, and that it would host no earnings call and give no fourth-quarter or full-year 2026 guidance. Accelerant third-quarter 2026 results release · as of
- The go-shop period expired on 22 September 2026 without Accelerant receiving an alternative acquisition proposal. Accelerant go-shop expiry release, 23 September 2026 · as of
- The merger agreement provides $20.25 per share in cash; Altamont affiliates with about 82% of voting rights agreed to support it, and financing is not a closing condition. Accelerant acquisition announcement, 13 August 2026 · as of
- TD Cowen downgraded Accelerant to Hold and lowered its price target to $20.25. Benzinga downgrade list, 30 September 2026 · as of
- Director Karen Sue Meriwether sold 542 shares at $19.62 on 21 August 2026. SEC Form 4, filed 25 August 2026 · as of
Sources
- Accelerant Announces Third Quarter 2026 Results · financialcontent.com ·
- Accelerant Announces Expiration of Go Shop Period · s205.q4cdn.com
- Accelerant Enters into Definitive Agreement to be Acquired by Thoma Bravo · s205.q4cdn.com
- Accelerant Holdings - Form DEFA14A · sec.gov
Related · shared themes
GPN
Global Payments
Global Payments trades on a reported $40 billion CD&R and GTCR buyout, and nine brokers raised targets after in-line third-quarter results…
ADT
ADT
ADT Inc. trades as a pending $10.00-per-share cash buyout by Thrive Holdings, so its shares are more likely to lag the S&P 500 than lead…
BMBL
Bumble
Bumble's shares are likely to trail the S&P 500 because they trade as a pending $6.05-per-share cash takeover by Ithaca Holdings, closing…
BRZE
Braze
Salesforce's agreed $47.50-per-share cash takeover of Braze caps the shares just under the offer, so they are more likely to lag the S&P…